Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy

Ulrich Keller*, Nikolas von Bubnoff, Christian Peschel, Justus Duyster

*Corresponding author for this work
2 Citations (Scopus)


In the past two decades there has been a tremendous increase in the understanding of the molecular basis of human malignancies. In a variety of neoplasms, specific molecular markers became part of disease classifications and are now routinely used to define specific entities. Molecular analyses discriminate prognostic groups, guide differential treatment strategies and identify targets for molecular defined cancer therapy. A battery of new drugs has been developed to specifically inhibit oncogenic pathways. For an increasing number of solid and haematological malignancies, the availability of molecular targeted drugs has fundamentally changed treatment algorithms. However, the diagnostic, prognostic and therapeutic impact of selected molecular markers is still limited in many cases. After all, the success of a molecular targeted therapy is clearly determined by the significance of the targeted structure for the biology of cancer and the ability of the malignant cell to evade specific inhibition.

Original languageEnglish
JournalJournal of Cellular and Molecular Medicine
Issue number4
Pages (from-to)805-817
Number of pages13
Publication statusPublished - 04.2010


Dive into the research topics of 'Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy'. Together they form a unique fingerprint.

Cite this